Boral Capital starts NeuroSense stock with Buy, $14 target

Published 12/05/2025, 13:02
Boral Capital starts NeuroSense stock with Buy, $14 target

On Monday, Boral (OTC:BOALY) Capital initiated coverage of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares with a Buy rating and a price target set at $14.00. Currently trading at $1.04, the stock sits well below both Boral’s target and the consensus analyst target of $7.50, according to InvestingPro data. The clinical-stage biotechnology company, which is focused on developing treatments for neurodegenerative diseases, caught the attention of the firm due to its promising lead candidate, PrimeC, aimed at combating amyotrophic lateral sclerosis (ALS). With a market capitalization of $25 million and a strong current ratio of 2.21, the company maintains more cash than debt on its balance sheet, though InvestingPro analysis indicates rapid cash consumption.

Jason Kolbert, an analyst at Boral Capital, expressed optimism about NeuroSense’s prospects. In his statement, he highlighted the company’s "differentiated mechanistic approach" and the "encouraging early clinical signals" as key factors for his positive outlook. He also noted the company’s "disciplined strategy toward regulatory and commercial milestones" as a basis for the Buy rating.

NeuroSense is working on a novel combination therapy platform that targets debilitating conditions such as ALS, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. The development of PrimeC has the potential to offer a new avenue for treatment for patients suffering from this currently incurable disease.

The $14.00 price target set by Boral Capital reflects a significant vote of confidence in the company’s future success and the potential market performance of its shares. The target suggests a substantial upside from the current trading levels of NeuroSense’s stock.

The initiation of coverage by Boral Capital is a key moment for NeuroSense Therapeutics as it continues to advance its clinical programs and seeks to bring new therapeutic options to the market for patients with neurodegenerative diseases. With the next earnings report due on May 28, investors seeking deeper insights into NRSN’s financial health, which InvestingPro rates as "Fair," can access additional analysis and 6 more exclusive ProTips through the platform.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.